Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 4456-4459, December 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanai, R.
Right arrow Articles by Nagasawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanai, R.
Right arrow Articles by Nagasawa, H.

Long-Term Effects of Prenatal and Neonatal Administration of 5ß-Dihydrotestosterone on Normal and Neoplastic Mammary Development in Mice1

Reiko Yanai, Takao Mori and Hiroshi Nagasawa

Pharmacology Division, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo 104 [R. Y., H. N.], and Zoological Institute, Faculty of Science, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113 [T. M.], Japan

The long-term effects on mammary glands of 5ß-dihydrotestosterone, considered to be biologically inactive, were studied in female SHN mice with mammary tumor virus. 5ß-Dihydrotestosterone was administered to mothers for 4 days from Day 12 to Day 15 of pregnancy (prenatal treatment) and to pups for 5 days of postnatal life (neonatal treatment) at daily doses of 1 mg and 200 µg, respectively. Neonatal treatment resulted in marked stimulation of spontaneous mammary tumorigenesis; all neonatally treated mice had palpable mammary tumors by 6.2 months of age, when mammary tumor incidences in the control mice and in mice treated prenatally with 5ß-dihydrotestosterone were 21.1 and 6.3%, respectively. Furthermore, neonatal treatment promoted normal and preneoplastic mammary growth and pituitary prolactin secretion and induced ovarian anovulatory syndrome in all mice. Prenatal treatment also increased the number of mammary hyperplastic alveolar nodules and induced a delayed anovulatory syndrome. These results have demonstrated that perinatal treatment with 5ß-dihydrotestosterone can induce such irreversible changes in the mammary glands, pituitary gland, ovaries, and genital tracts as those seen with other biologically active steroid hormones.

1 This work was supported in part by Grant-in-aid 101089 for Cancer Research from the Ministry of Education, Science and Culture, Japan.

Received 2/ 3/77. Accepted 9/ 7/77.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.